Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | PPARD | Q03181 | 6/20 | 0.44 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL9857695 | 0.95 | CA1 (0.43) | CES2CES1LMNAMEN1KMT2A | |
| Butyl Alcohol SCHEMBL11686833 | 0.85 | ALDH1A1 (0.52) | CES2CES1LMNAMEN1KMT2A | |
| Butyl Alcohol SCHEMBL9545057 | 0.83 | ALDH1A1 (0.50) | CES2CES1LMNAMEN1KMT2A | |
| Propanol SCHEMBL15333015 | 0.81 | TSHR (0.32) | CES2CES1TSHRALDH1A1TDP1 | |
| SCHEMBL24478517 | 0.78 | CES2 (0.59) | CES2CES1MEN1KMT2AFAAH | |
| SCHEMBL8090670 | 0.78 | CES2 (0.59) | CES2CES1MEN1KMT2AFAAH | |
| SCHEMBL4758346 | 0.78 | CES2 (0.59) | CES2CES1MEN1KMT2AFAAH | |
| Octane SCHEMBL4906557 | 0.78 | CES2 (0.50) | CES2CES1LMNAMEN1KMT2A | |
| Heptane SCHEMBL9063842 | 0.78 | CES2 (0.50) | CES2CES1LMNAMEN1KMT2A | |
| Methyl Alcohol SCHEMBL8058445 | 0.76 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853599-B1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LTD (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8334303-B2 | Specifically mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate (SB 268091); use as antibiotic; crystallization from isopropanol; improved bioavailability, and/or physical properties, for example solubility or flow properties | GLAZO GROUP LIMITED (GB) | 2012-12-18 | — | — | US | disclosed |
| US-8207191-B2 | Process, salts, composition and use | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110144151-A1 | NOVEL PROCESS, SALTS, COMPOSITION AND USE | GLAXO GROUP LIMITED | 2011-06-16 | — | — | US | disclosed |
| US-7875630-B2 | reacting exo-8-methyl-8-azabicyclo[3.2.1]octan-3-thiol with mutilin 14-methanesulfonyloxyacetate in the presence of a tetra-n-butylammonium hydrogensulfate phase transfer catalyst, 4-methyl-2-pentanone, and aqueous NaOH to form mutilin 14-(exo-8-methyl-8-azabicyclo[3.2. 1]oct-3-ylsulfanyl)-acetate | GLAXO GROUP LIMITED | 2011-01-25 | — | — | US | disclosed |
| EP-2181995-A2 | Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate | Glaxo Group Limited (GB) | 2010-05-05 | — | — | EP | disclosed |
| EP-1663220-B1 | NOVEL PROCESS FOR THE PREPARATION OF PLEUROMUTILIN DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080161342-A1 | Novel Polymorph of Mutilin | GLAXO GROUP LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1853599-A1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LIMITED (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1663220-A4 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276503-A1 | Novel process salts compositions and use | GLAXO GROUP LIMITED | 2006-12-07 | — | — | US | disclosed |
| WO-2006092334-A1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| EP-1663220-A1 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023257-A1 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144151-A1 | NOVEL PROCESS, SALTS, COMPOSITION AND USE | PLEC, MITF, MYOC | CES2 4665/4885CES1 4247/4885LMNA 3459/4885 |
| US-20080161342-A1 | Novel Polymorph of Mutilin | AMPD1, MSH2, MDN1 | CES2 4838/4885CES1 4520/4885LMNA 3721/4885 |
| US-20060276503-A1 | Novel process salts compositions and use | MYOC, MITF, MDN1 | CES2 4667/4885CES1 4446/4885LMNA 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.